Impact of central venous port implantation method and access choice on outcomes

Table 1 Demographic characteristics of 200 central venous port-implanted patients

Characteristic	Parameters	n (%)
Age	Min-max: 20-84	200 (100)
	Median: 62
	mean ± SD: 59.6 ± 12.1
Duration of port use in mo	Min-max: 0-93	200 (100)
	Median: 8
	mean ± SD: 13.5 ± 15.7
Sex	Female	99 (49.5)
	Male	101 (50.5)
Side	Right	186 (93.0)
	Left	14 (7.0)
Number of chemotherapeutic drug(s)	1	87 (43.5)
	2	83 (41.5)
	3	30 (15.0)
Complication	Present	20 (10)
	Absent	180 (90)
Clavien-Dindo severity classification	0-I	179 (89.5)
	II	7 (3.5)
	III	14 (7.0)

SD: Standard deviation.

Table 2 Primary diagnosis of 200 central venous port implanted patients

Primary diagnosis	n (%)
Gastrointestinal system cancers	115 (57.5)
Breast cancers	28 (14.0)
Pancreaticobiliary system cancers	26 (13.0)
Head and neck cancers	11 (5.0)
Gynecologic cancers	9 (4.5)
Soft tissue sarcomas	4 (2.0)
Lung cancers	3 (1.5)
Lymphomas	2 (1.0)
Renal cell cancer	1 (0.5)
Adenocarcinoma of unknown origin	1 (0.5)

Table 3 Comparison of central venous port-implanted patients according to the access method, n (%)

Parameters	Group 1	Group 2	P value
Age, mean ± SD (median)	58.2 ± 11.3 (61.0)	60.9 ± 12.7 (63.5)	0.0601
Port use duration in mo, mean ± SD (median)	12.3 ± 9.9 (9.5)	14.7 ± 19.8 (8.0)	0.3551
Sex			0.0662
Female	43 (43)	56 (56)
Male	57 (57)	44 (44)
Side			0.2682
Right	91 (91)	95 (95)
Left	9 (9)	5 (5)
Number of the chemotherapy drug(s)			0.4732
1	46 (46)	41 (41)
2	42 (42)	41 (41)
3	12 (12)	18 (18)
Complications			0.0002
Present	2 (2)	18 (18)
Absent	98 (98)	82 (82)
Clavien-Dindo complication severity classification			0.0002
0-I	98 (98)	81 (81)
II	1 (1)	6 (6)
III	1 (1)	13 (13)

¹Mann-Whitney U test.

²χ² test.

Data are presented as mean ± SD and median, or n (%). Group 1: Patients whose jugular veins were used; group 2: Patients whose subclavian veins were used.